|
Variable
|
n
|
Percent
|
|---|
|
Median Age (years)
|
60.7 (range 21–92)
|
|
Median Tumor Volume (cc)
|
8.7 (range 0.67 – 62.2)
|
|
Gender:
|
|
Male
|
58
|
25.9%
|
|
Female
|
166
|
74.1%
|
|
Location:
|
|
Cavernous sinus
|
66
|
29.5%
|
|
Parasellar
|
9
|
4.0%
|
|
Sphenoid/clinoid
|
65
|
29.0%
|
|
CPA
|
32
|
14.3%
|
|
Clivus
|
7
|
3.1%
|
|
Sellar/suprasellar
|
16
|
7.1%
|
|
Planum
|
15
|
6.7%
|
|
Craniocervical
|
13
|
5.8%
|
|
Other
|
1
|
0.4%
|
|
Laterality
|
|
Left
|
95
|
42.4%
|
|
Right
|
84
|
37.5%
|
|
Midline/Bilateral
|
44
|
19.6%
|
|
Unknown
|
1
|
0.4%
|
|
Symptoms at time of Radiation
|
|
Symptomatic
|
205
|
91.5%
|
|
Asymptomatic
|
19
|
8.6%
|
|
Intensity Modulate Radiation Therapy
|
|
Yes
|
41
|
18.3%
|
|
No
|
183
|
81.7%
|
|
Neurofibramatosis-2
|
3
|
1.4%
|
|
Treatment Group*:
|
|
Radiation only
|
115
|
51.3%
|
|
Adjuvant radiation
|
40
|
17.9%
|
|
Progression after surgery
|
58
|
25.9%
|
|
Re-irradiation
|
11
|
4.9%
|
|
Pathology
|
|
No pathologic diagnosis
|
112
|
50.0%
|
|
WHO grade I
|
108
|
48.2%
|
|
WHO grade II
|
4
|
1.8%
|
|
Dose
|
|
> 52.5 Gy
|
125
|
55.8%
|
|
<= 52.2 Gy
|
99
|
44.2%
|
- * Per treatment course. Seven patients in the radiation only, adjuvant radiation or progression after surgery groups are also present in the re-irradiation group because they underwent a second course of fractionated stereotactic radiation therapy.
